The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Benzodiazepine use and risk of Alzheimer's disease: case-control study
Open accessAbstract
OBJECTIVES: To investigate the relation between the risk of Alzheimer's disease and exposure to benzodiazepines started at least five years before, considering both the dose-response relation and prodromes (anxiety, depression, insomnia) possibly linked with treatment. DESIGN: Case-control study. SETTING: The Quebec health insurance program database (RAMQ). PARTICIPANTS: 1796 people with a first diagnosis of Alzheimer's disease and followed up for at least six years before were matched with 7184 controls on sex, age group, and duration of follow-up. Both groups were randomly sampled from older people (age >66) living in the community in 2000-09. MAIN OUTCOME MEASURE: The association between Alzheimer's disease and benzodiazepine use started at least five years before diagnosis was assessed by using multivariable conditional logistic regression. Ever exposure to benzodiazepines was first considered and then categorised according to the cumulative dose expressed as prescribed daily doses (1-90, 91-180, >180) and the drug elimination half life. RESULTS: Benzodiazepine ever use was associated with an increased risk of Alzheimer's disease (adjusted odds ratio 1.51, 95% confidence interval 1.36 to 1.69; further adjustment on anxiety, depression, and insomnia did not markedly alter this result: 1.43, 1.28 to 1.60). No association was found for a cumulative dose <91 prescribed daily doses. The strength of association increased with exposure density (1.32 (1.01 to 1.74) for 91-180 prescribed daily doses and 1.84 (1.62 to 2.08) for >180 prescribed daily doses) and with the drug half life (1.43 (1.27 to 1.61) for short acting drugs and 1.70 (1.46 to 1.98) for long acting ones). CONCLUSION: Benzodiazepine use is associated with an increased risk of Alzheimer's disease. The stronger association observed for long term exposures reinforces the suspicion of a possible direct association, even if benzodiazepine use might also be an early marker of a condition associated with an increased risk of dementia. Unwarranted long term use of these drugs should be considered as a public health concern.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
What is cognitive reserve? Theory and research application of the reserve concept
STERN, Y. (2002) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617702813248 · Cited by 3,951
Lyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002) · JAMA · doi:10.1001/jama.288.12.1475 · Cited by 2,049
Influence of education and occupation on the incidence of Alzheimer's disease
Stern, Y. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370056032 · Cited by 1,434
Depression and risk of developing dementia
Byers, A. L., & Yaffe, K. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.60 · Cited by 1,265
Brain reserve and dementia: a systematic review
VALENZUELA, M. J., & SACHDEV, P. (2006) · Psychological Medicine · doi:10.1017/s0033291705006264 · Cited by 932
Mild cognitive impairment: Long-term course of four clinical subtypes
Busse, A., Hensel, A., Gühne, U., Angermeyer, M. C., & Riedel-Heller, S. G. (2006) · Neurology · doi:10.1212/01.wnl.0000249117.23318.e1 · Cited by 561
Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment
Dotson, V. M., Beydoun, M. A., & Zonderman, A. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e62124 · Cited by 385
Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease
Li, J., Wang, Y. J., Zhang, M., Xu, Z. Q., Gao, C. Y., Fang, C. Q., Yan, J. C., & Zhou, H. D. (2011) · Neurology · doi:10.1212/wnl.0b013e318217e7a4 · Cited by 367
Cited by
Epileptic activity in Alzheimer’s disease: Causes and clinical relevance
Vossel, K. A., Tartaglia, M. C., Nygaard, H. B., Zeman, A. Z., & Miller, B. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30044-3 · Cited by 590
10-year trajectories of depressive symptoms and risk of dementia: a population-based study
Mirza, S. S., Wolters, F. J., Swanson, S. A., Koudstaal, P. J., Hofman, A., Tiemeier, H., & Ikram, M. A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00097-3 · Cited by 385
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“It has been associated with increased risk for dementia [57,58].”
BackgroundGray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A., Crane, P. K., & Larson, E. B. (2016) · BMJ · doi:10.1136/bmj.i90 · Cited by 233
Towards a Better Understanding of GABAergic Remodeling in Alzheimer’s Disease
Govindpani, K., Calvo-Flores Guzmán, B., Vinnakota, C., Waldvogel, H., Faull, R., & Kwakowsky, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081813 · Cited by 208
Reeve, E., Ong, M., Wu, A., Jansen, J., Petrovic, M., & Gnjidic, D. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2257-8 · Cited by 192
Lucchetta, R. C., da Mata, B. P. M., & Mastroianni, P. D. C. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2170 · Cited by 130
The Effects of Mind-Body Interventions on Sleep Quality: A Systematic Review
Neuendorf, R., Wahbeh, H., Chamine, I., Yu, J., Hutchison, K., & Oken, B. S. (2015) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2015/902708 · Cited by 116
Kroll, D. S., Nieva, H. R., Barsky, A. J., & Linder, J. A. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3740-0 · Cited by 94
Maust, D. T., Blow, F. C., Wiechers, I. R., Kales, H. C., & Marcus, S. C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10713 · Cited by 93
No end in sight: benzodiazepine use in older adults in the United States.
Maust, D. T., Kales, H. C., Wiechers, I. R., Blow, F. C., & Olfson, M. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14379 · Cited by 82
“Use is a particular concern in older adults, given associations between benzodiazepines and a variety of adverse outcomes, including falls,(5) fractures,(6) motor vehicle accidents,(7) impaired cognition,(8,9) and dementia.(10) Due to the accumulation of health and safety concerns in older adults, the American Geriatr…”
BackgroundNafti, M., Sirois, C., Kröger, E., Carmichael, P.-H., & Laurin, D. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028019882037 · Cited by 73
Multifocal Cognitive Dysfunction in High-Dose Benzodiazepine Users: A Cross-Sectional Study
Federico, A., Tamburin, S., Maier, A., Faccini, M., Casari, R., Morbioli, L., & Lugoboni, F. (2017) · Neurological Sciences · doi:10.1007/s10072-016-2732-5 · Cited by 60
Central and peripheral circadian clocks and their role in Alzheimer's disease
Chauhan, R., Chen, K.-F., Kent, B. A., & Crowther, D. C. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030627 · Cited by 58
“In Drosophila, there have been similar findings, in particular the boosting of the cleavage of APPL (theDrosophila orthologue of APP) by β-secretase resulted in behavioural arrhythmia and reduced the expression of the clock gene per (Blake et al., 2015).”
BackgroundPanes, A., Pariente, A., Bénard-Laribière, A., Lassalle, R., Dureau-Pournin, C., Lorrain, S., Tournier, M., & Fourrier-Réglat, A. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0966-3 · Cited by 50
Self-citationDuffy, J. F., Wang, W., Ronda, J. M., & Czeisler, C. A. (2022) · Journal of Pineal Research · doi:10.1111/jpi.12801 · Cited by 43
Martin, P., & Tannenbaum, C. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0432-5 · Cited by 41
Wright, A., Diebold, J., Otal, J., Stoneman, C., Wong, J., Wallace, C., & Duffett, M. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0322-5 · Cited by 43
Unified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy
Nehls, M. (2016) · Journal of Molecular Psychiatry · doi:10.1186/s40303-016-0018-8 · Cited by 41
Li, G., Kim, C., Kim, J., Yoon, H., Zhou, H., & Kim, J. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150024 · Cited by 39
Long-term use of tamoxifen reduces the risk of dementia: A nationwide population-based cohort study
Sun, L.-M., Chen, H.-J., Liang, J.-A., & Kao, C.-H. (2016) · QJM · doi:10.1093/qjmed/hcv072 · Cited by 39
Dyer, A. H., Murphy, C., Lawlor, B., Kennelly, S. P., Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.08.006 · Cited by 39
Davies, S. J., Rudoler, D., de Oliveira, C., Huang, A., Kurdyak, P., & Iaboni, A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069096 · Cited by 32
Richardson, K., Mattishent, K., Loke, Y. K., Steel, N., Fox, C., Grossi, C. M., Bennett, K., Maidment, I., Boustani, M., Matthews, F. E., et al. (2019) · American Journal of Epidemiology · doi:10.1093/aje/kwz073 · Cited by 36
Addictive potential of novel treatments for refractory depression and anxiety
Kolar, D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167538 · Cited by 37
Hafdi, M., Hoevenaar-Blom, M. P., Beishuizen, C. R. L., Moll van Charante, E. P., Richard, E., & van Gool, W. A. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.05.010 · Cited by 37
Landolt, S., Rosemann, T., Blozik, E., Brüngger, B., & Huber, C. A. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s290104 · Cited by 34
Accelerating Alzheimer's disease drug innovations from the research pipeline to patients
Goldman, D. P., Fillit, H., & Neumann, P. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.007 · Cited by 30
Clinical Methodology Matters in Epidemiology: Not All Benzodiazepines Are the Same
Cosci, F., Guidi, J., Balon, R., & Fava, G. A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000437201 · Cited by 27
Zhou, M., Tang, J., Li, S., Li, Y., & Zhao, M. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.1029554 · Cited by 24
Development of a video-delivered relaxation treatment of late-life anxiety for veterans
Gould, C. E., Zapata, A. M. L., Bruce, J., Bereknyei Merrell, S., Wetherell, J. L., O'Hara, R., Kuhn, E., Goldstein, M. K., & Beaudreau, S. A. (2017) · International Psychogeriatrics · doi:10.1017/s1041610217000928 · Cited by 23
Association Between the Use of Hypnotics and the Risk of Alzheimer's Disease
Jeong, W., Joo, J. H., Kim, H., Kim, Y. K., Park, E.-C., & Jang, S.-I. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201319 · Cited by 11
(2018) · Europe PMC (PubMed Central) · Cited by 10
Jung, M. E., Metzger, D. B., & Hall, J. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172873 · Cited by 8
Wu, D., Hu, Y., Song, M., & Li, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.634948 · Cited by 7
Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine · doi:10.1017/s0033291726104887
Metadata
- Authors
- Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2014-09-09
- Volume
- 349
- Issue
- sep09 2
- Pages
- g5205-g5205
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2000736071
- Cited by
- 558
- References
- 18
- FWCI
- 43.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
